Finance-Funding

  1. How To Navigate Pharma Collaboration And Licensing Agreements 2/1/2017

    Collaboration and licensing agreements are an indispensable business strategy for both pharmaceutical companies with commercial capabilities and biotech companies developing novel therapeutics.

  2. Orphan Drug Incentives & Innovations On The Rise 1/1/2017

    The FDA and EMA are giving unprecedented support to addressing the rare disease need, aiming efforts largely at the biotech and specialty pharma companies that are at the forefront of orphan drug development.

  3. Are You Ready To Fund Your Life Sciences Startup? 10/1/2016

    If you have an idea for a life sciences product geared toward meeting an unmet medical need, you have probably given a lot of thought as to what makes it special, as well as why insurance companies should be willing to pay for it. But no matter how differentiated or breakthrough your innovation might be, if you haven’t considered how to finance your vision, it likely won’t ever see the light of day.

  4. 7 Secrets VC Investors Want Biopharma Heads of R&D To Know: People And Profits - Part 4 5/30/2016

    When a pharma is divesting an asset, how important is it to take the asset and the people (i.e., the champions and asset experts) when determining your capital allocation? When do you say that the people have to be included, and what are some of the considerations on the intellectual capital, besides the actual product?

  5. 7 Secrets VC Investors Want Biopharma Heads of R&D To Know: Investing Intellectual Capital In Assessing Intellectual Property - Part 3 5/23/2016

    Imagine you get that call from a Big Pharma. They tell you they are divesting X, which is not part of a strategic reprioritization. In other words, they’re not exiting that therapeutic category, just this particular target/product. How do you know what to look for in determining if it is a quality asset or if it actually belongs in the garbage dump?

  6. 7 Secrets VC Investors Want Biopharma Heads of R&D To Know 5/3/2016

    Having had the opportunity to attend an invitation-only event focused on biopharmaceutical R&D, what follows is a behind the scenes glimpse of what VCs look for when engaging with biopharmaceutical company heads of R&D as they weed, seed, and water those assets within their portfolios.

  7. The Art Of Optimizing Small Biotech Market Caps – From Scientific Dreams To Strategic Reality 4/29/2014

    Our roundtable — held during the confluence of industry events surrounding the JP Morgan Healthcare Conference in January 2014 — continued to explore the effects of valuation and market cap on such a company and what it can do to optimize its value at every stage of its development.

  8. The Art Of Optimizing Small Biotech Market Caps – From Scientific Dreams To Strategic Reality 4/1/2014

    As the sun cast a rosy glow over the city’s horizon, bathing us in dawn light through the wide windows of our meeting room, a small group of company executives and investment experts shared breakfast and chatted before taking up the business at hand. Their purpose here: Trade insights across the table into how small biotech companies can achieve the best possible market capitalization at every stage of their development.

  9. Crowdfunding for Life Sciences Companies 12/6/2013

    I recently participated in a panel discussion on crowdfunding for biosciences, and I wanted to share some of the ideas we discussed. Although focused on life sciences companies, many of the issues are applicable to tech companies too.

  10. Taking Biotech Public: To IPO Or Not To IPO 8/29/2013

    The window for IPO is now cautiously opening, and biotechs are starting to take advantage, but are IPOs the best route for everyone? “Investors are seeing the large biotech companies are performing well, which creates a cascading effect, raising the values of smaller companies and increasing the appetite for IPOs,” says Glen Giovannetti, global life science sectors leader at Ernst & Young.